JP2007512237A5 - - Google Patents

Download PDF

Info

Publication number
JP2007512237A5
JP2007512237A5 JP2006536948A JP2006536948A JP2007512237A5 JP 2007512237 A5 JP2007512237 A5 JP 2007512237A5 JP 2006536948 A JP2006536948 A JP 2006536948A JP 2006536948 A JP2006536948 A JP 2006536948A JP 2007512237 A5 JP2007512237 A5 JP 2007512237A5
Authority
JP
Japan
Prior art keywords
ibandronate sodium
ray
crystalline form
reflection
sodium crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006536948A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007512237A (ja
JP4559431B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/030500 external-priority patent/WO2006024024A2/en
Publication of JP2007512237A publication Critical patent/JP2007512237A/ja
Publication of JP2007512237A5 publication Critical patent/JP2007512237A5/ja
Application granted granted Critical
Publication of JP4559431B2 publication Critical patent/JP4559431B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2006536948A 2004-08-23 2005-08-23 固体及び結晶イバンドロネートナトリウム及びその調製方法 Expired - Lifetime JP4559431B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60402604P 2004-08-23 2004-08-23
US69086705P 2005-06-16 2005-06-16
PCT/US2005/030500 WO2006024024A2 (en) 2004-08-23 2005-08-23 Solid and crystalline ibandronate sodium and processes for preparation thereof

Publications (3)

Publication Number Publication Date
JP2007512237A JP2007512237A (ja) 2007-05-17
JP2007512237A5 true JP2007512237A5 (https=) 2008-02-14
JP4559431B2 JP4559431B2 (ja) 2010-10-06

Family

ID=35968334

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006536948A Expired - Lifetime JP4559431B2 (ja) 2004-08-23 2005-08-23 固体及び結晶イバンドロネートナトリウム及びその調製方法

Country Status (12)

Country Link
US (1) US7563918B2 (https=)
EP (2) EP1713489B1 (https=)
JP (1) JP4559431B2 (https=)
KR (2) KR20070043043A (https=)
CN (1) CN101022812A (https=)
AT (2) ATE520406T1 (https=)
CA (1) CA2576659A1 (https=)
DE (2) DE202005021414U1 (https=)
ES (1) ES2358269T3 (https=)
IL (1) IL181298A (https=)
PT (2) PT1713489E (https=)
WO (1) WO2006024024A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2655435T3 (es) 2003-09-12 2018-02-20 Amgen Inc. Formulación de disolución rápida de cinacalcet
CN101111504B (zh) * 2005-02-01 2011-12-21 霍夫曼-拉罗奇有限公司 伊班膦酸盐多晶型物a
CA2594717C (en) * 2005-02-01 2015-01-20 F. Hoffmann-La Roche Ag Ibandronate polymorph b
WO2007074475A2 (en) * 2005-12-27 2007-07-05 Natco Pharma Limited Novel polymorphic forms of ibandronate
WO2008014510A2 (en) * 2006-07-28 2008-01-31 Dr. Reddy's Laboratories Limited Crystalline form a of ibandronic acid and process for the preparation
US20090012047A1 (en) * 2006-11-16 2009-01-08 Eran Turgeman Crystalline forms of ibandronate sodium
CA2570949A1 (en) 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
SI2144919T1 (sl) 2007-04-11 2016-02-29 F. Hoffmann-La Roche Ag Večstopenjska sinteza ibandronata
US20100125149A1 (en) * 2007-04-19 2010-05-20 Dr. Reddy's Laboratories Ltd. Ibandronate sodium polymorphs
US20090042839A1 (en) * 2007-08-09 2009-02-12 Sharon Avhar-Maydan Crystalline forms of ibandronate sodium
EP2212338B1 (en) * 2007-10-26 2013-07-10 Chemo Ibérica, S.A. Polymorphic forms of ibandronate sodium and processes for preparation thereof
EP2128166A1 (en) 2008-05-20 2009-12-02 Chemo Ibérica, S.A. Polymorphic forms of Ibandronate sodium and processes for preparation thereof
WO2009061336A1 (en) * 2007-11-05 2009-05-14 Teva Pharmaceutical Industries Ltd. Amorphous and crystalline forms of ibandronate disodium
EP2180003A1 (en) 2008-10-21 2010-04-28 Zentiva, k.s. Preparation of ibandronate trisodium
BRPI1008560B1 (pt) 2009-02-13 2021-08-31 Boehringer Ingelheim International Gmbh Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dpp-iv e opcionalmente um outro agente antidiabético e usos dos mesmos
EP2429390B1 (en) 2009-05-15 2015-09-09 Nox Medical System and methods using flexible capacitive electrodes for measuring biosignals
WO2011016738A1 (en) 2009-08-05 2011-02-10 Zaklady Farmaceutyczne Polpharma Sa A process for the synthesis of 1-hydroxy-3-(n-methylpentylamino) propylidene bisphosphonic acid monosodium salt, monohydrate
PE20121524A1 (es) 2010-01-27 2012-12-03 Viiv Healthcare Co Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapeuticos
EP2584962B1 (en) 2010-06-25 2014-09-10 Nox Medical ehf. Biometric belt connector
SMT201700124T1 (it) 2010-09-03 2017-05-08 Valneva Austria Gmbh Polipeptide isolato delle proteine di tossina a e tossina b di c. difficile e relativi usi
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
WO2013179305A1 (en) * 2012-06-01 2013-12-05 Hetero Research Foundation Ibandronate sodium solid dispersion
WO2014170909A2 (en) 2013-04-01 2014-10-23 Hetero Research Foundation Process for pomalidomide
EP3065638B1 (en) 2013-11-06 2024-01-10 Nox Medical ehf. Method, apparatus, and system for measuring respiratory effort
AR099354A1 (es) 2013-11-15 2016-07-20 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos
WO2018033889A1 (en) 2016-08-19 2018-02-22 Nox Medical Method, apparatus, and system for measuring respiratory effort of a subject
US11896386B2 (en) 2017-06-02 2024-02-13 Nox Medical Ehf Coherence-based method, apparatus, and system for identifying corresponding signals of a physiological study
WO2019049097A1 (en) 2017-09-08 2019-03-14 Nox Medical Ehf SYSTEM AND METHOD FOR NON-INVASIVE DETERMINATION OF AN INTERNAL COMPONENT OF RESPIRATORY EFFORT

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
JP2639721B2 (ja) 1988-12-27 1997-08-13 富士重工業株式会社 内燃機関の燃焼室
US5652227A (en) * 1995-01-30 1997-07-29 Teronen; Olli Pekka Inhibition of the degradation of connective tissue matrix protein components in mammals
DE19637890A1 (de) * 1996-09-17 1998-03-19 Max Planck Gesellschaft Biphosphonat-Liposomen
DE19828450A1 (de) * 1998-06-26 1999-12-30 Hassan Jomaa Bisphosphonsäuren und deren Derivate enthaltende Arzneimittel zur Prophylaxe und zur Behandlung von Autoimmunkrankheiten sowie von Allergien
EP0998932A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
EP0998933A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
PL351674A1 (en) * 1999-05-21 2003-05-19 Novartis Ag Use of bisphosphonic acids for treating angiogenesis
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
JP3923800B2 (ja) * 2000-05-05 2007-06-06 エフ.ホフマン−ラ ロシュ アーゲー ビスホスホン酸またはそれらの塩を含む、皮下投与のためのゲル様医薬組成物
ES2394211T3 (es) * 2000-06-20 2013-01-23 Novartis Ag Procedimiento de administración de bifosfonatos
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
MXPA02001219A (es) * 2001-02-01 2005-06-06 Riderway Corp Composicion farmaceutica liquida para el tratamiento de enfermedades oseas.
ITMI20020908A1 (it) 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione di sodio alendronato
KR20060058151A (ko) * 2002-05-10 2006-05-29 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
BR0310087A (pt) * 2002-05-17 2005-08-16 Wyeth Corp Veìculos sólidos injetáveis para ácido hialurÈnico para aplicação de proteìnas osteogênicas
ES2291749T5 (es) * 2002-12-20 2011-07-21 F. Hoffmann-La Roche Ag Formulación de altas dosis de ibandronato.
ATE508134T1 (de) * 2003-12-23 2011-05-15 Alchymars S P A Amorphe form das natriumsalzes der ibandronsäure
WO2006002348A2 (en) * 2004-06-23 2006-01-05 Teva Pharmaceutical Industies Ltd. Solid and crystalline ibandronic acid
CA2594717C (en) 2005-02-01 2015-01-20 F. Hoffmann-La Roche Ag Ibandronate polymorph b
CN101111504B (zh) 2005-02-01 2011-12-21 霍夫曼-拉罗奇有限公司 伊班膦酸盐多晶型物a
WO2007074475A2 (en) 2005-12-27 2007-07-05 Natco Pharma Limited Novel polymorphic forms of ibandronate

Similar Documents

Publication Publication Date Title
JP2007512237A5 (https=)
JP2007302683A5 (https=)
JP2011527299A5 (https=)
JP2009235100A5 (https=)
JP2014005302A5 (https=)
HRP20171175T1 (hr) Novi triciklički spojevi
JP2018024682A5 (https=)
JP2023002516A5 (https=)
FI2629097T1 (fi) Nrf2-seulontatestejä ja niihin liittyviä menetelmiä ja koostumuksia
HRP20140666T1 (hr) Kristalni oblici derivata 2-tiazolil-4-kinolinil-oksi, snažnog hcv-inhibitora
JP2013509429A5 (https=)
JP2009545527A5 (https=)
JP2014523445A5 (https=)
JP2010513478A5 (https=)
HRP20181048T1 (hr) Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja
HRP20150584T1 (hr) Soli i polimorfi tetraciklinskog spoja
JP2011500621A5 (https=)
HRP20140004T1 (hr) Novi spojevi 951: bifeniloksipropanska kiselina kao crth2 modulator i intermedijeri
NZ592383A (en) Pharmaceutical composition of a potent hcv inhibitor for oral administration
JP2008518904A5 (https=)
HRP20231588T3 (hr) Kombinacija koja sadrži stabilni kristal 4-oksokinolinskog spoja
MA28133A1 (fr) FORME CRISTALLINE ßd DU CHLORHYDRATE DE L'IVABRADINE, SON PROCEDE DE PREPARATION, ET LES COMPOSITIONS PHARMACEUTIQUES QUI LA CONTIENNENT.
MX2010007374A (es) Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos.
HRP20150062T1 (hr) Farmaceutski pripravak koji sadrži optički aktivan spoj koji sadrži agonist receptora trombopoietina i njegov međuprodukt
JP2013514980A5 (https=)